Japan headquartered pharma company Eisai Co. has announced that its French sales subsidiary Eisai S.A.S. has entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the Territory” for the antipsychotic, Loxapac (generic name: loxapine) and the Parkinson's disease treatment Parkinane LP (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics, based in UK.
Two pathways have long been of interest to researchers studying colon cancer: Notch and MAPK. But drugs designed to target either pathway have proven disappointing. Now a team of researchers in Germany has made a discovery that sheds light on those disappointments—and provides insight that could improve colon cancer treatment.
The alarm bells are ringing at Alexza Pharmaceuticals ($ALXA) as the small biotech announced a weak set of financials and the stark warning that without help, it will likely shut down operations by the summer.
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has reacquired U.S. commercial rights for ADASUVE® (loxapine) inhalation powder from Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd. Alexza and Teva have also restructured the obligations under the outstanding note from Teva. In conjunction with the reacquisition of U.S. ADASUVE rights, Alexza and Teva have completed a transition agreement, which is intended to provide continued availability of ADASUVE by Alexza to patients and health care providers.
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced interim results of its Phase 2a study of AZ-002 (Staccato® alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study. AZ-002 is being developed for the management of epilepsy in patients with acute repetitive seizures (ARS). ARS occurs in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a regular regimen of anti-epileptic drugs.